Safety and immunogenicity of ChAd63 Pfs-25IMX313 alone and with MVA Pfs25-IMX313 (VAC062)

This is a clinical trial in which healthy volunteers will be administered one or two experimental malaria vaccines. ChAd Pfs-IMX313 will either be administered alone or with MVA Pfs25-IMX313 in a prime-boost regime.

All vaccines will be administered intramuscularly.
Group 1 will receive one dose of ChAd63 Pfs25-IMX313 at 5×10^9 vp.
Group 2A will receive one dose of ChAd63 Pfs-IMX313 at 5×10^10 vp.
Group 2B will receive one dose of ChAd63 Pfs-IMX313 at 5×10^10 vp and one dose of MVA Pfs25-IMX313 at 1×10^8 pfu eight weeks later.
Group 2C will receive one dose of ChAd63 Pfs25-IMX313 at 5×10^10 vp and one dose of MVA Pfs25-IMX313 at 2×10^8 pfu eight weeks later.

Study type: Interventional
Enrollment: 26 participant
Primary purpose: Prevention
Allocation: Non-Randomized
Interventional Model: Parallel assignment
Masking : Open label
NCT number: NCT02532049
Phase: Phase I

Clinical trial registration

Vaccines

Oct 2015 — May 2017

United Kingdom